
- /
- Supported exchanges
- / US
- / ORIC.NASDAQ
Oric Pharmaceuticals Inc (ORIC NASDAQ) stock market data APIs
Oric Pharmaceuticals Inc Financial Data Overview
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Oric Pharmaceuticals Inc data using free add-ons & libraries
Get Oric Pharmaceuticals Inc Fundamental Data
Oric Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -145 475 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.44
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oric Pharmaceuticals Inc News

JPMorgan biotech/pharma analysts hold analyst/industry conference call
US SMid Biotech Analyst Rama and US Major & Specialty Pharmaceuticals Analyst Schott, along with Dr. Charles Ryan, Genitourinary Medical Oncologist at Memorial Sloan Kettering Cancer Center discuss th...


Oric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholders
* Oric Pharmaceuticals (NASDAQ:ORIC [https://seekingalpha.com/symbol/ORIC]) filed a prospectus to resale 19.23M shares of common stock. * The company will not receive any proceeds from the sale o...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
Shares of ORIC Pharmaceuticals ORIC surged more than 20% in the pre-market hours today after announcing potentially best-in-class preliminary efficacy and safety data from the ongoing early-stage stud...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.